Beovu® Pre-filled Syringe for Wet AMD and Diabetic Macular Edema

What Beovu® Is and How It Works

Beovu® (brolucizumab) is an anti-VEGF intravitreal injection used to treat neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). The Beovu Pre-filled Syringe contains a single 6 mg dose for injection into the vitreous by an eye care specialist. Patients paying without insurance often compare Canadian pricing to lower their out-of-pocket costs.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing.

Brolucizumab binds vascular endothelial growth factor (VEGF), which drives abnormal retinal blood vessel growth and leakage. By suppressing VEGF, Beovu reduces retinal fluid, stabilizes or improves vision, and allows longer intervals between injections in many patients.

We source authentic brand products through licensed, vetted partner pharmacies worldwide to maintain quality, selection, and competitive pricing.

Dosage and Usage

• Indication: neovascular (wet) AMD and DME, as prescribed by a retina specialist or ophthalmologist.
• Strength/Form: 6 mg/0.05 mL in a sterile, single-use pre-filled syringe.
• Administration: intravitreal injection performed under aseptic conditions by a qualified eye care professional; not for self-injection.
• Loading phase: typically one injection every month for 3 doses.
• Maintenance: dosing every 8 to 12 weeks, individualized based on disease activity and visual/retinal fluid response.
• Monitoring: patients are evaluated for intraocular inflammation, retinal vasculitis or occlusion, endophthalmitis, intraocular pressure changes, and vision changes.
• Missed dose: clinics generally reschedule the injection promptly to maintain disease control.
• Use limitations: single-use only; discard any unused portion. Do not mix with other products or co-administer in the same eye on the same day with other intravitreal agents.

• Storage: store refrigerated at 2–8 °C (36–46 °F) in the original carton; protect from light; do not freeze; do not shake.
• Before clinic transport: keep the carton cold using gel packs; avoid direct contact with ice; keep upright and protected.
• At the clinic: allow the syringe to reach room temperature in its sealed pack; keep sterile and protected from light until use.
• Travel: plan delivery when someone can refrigerate on arrival. If you travel with your medicine, use an insulated container with cool packs and avoid heat.
• Disposal: return used sharps to a clinic or a pharmacy sharps program; do not place in household trash.

Benefits and Savings

Beovu can dry retinal fluid quickly and sustain control with fewer injections for many patients. The pre-filled syringe format supports consistent dosing and efficient clinic workflow. After the loading phase, some patients extend to 12-week intervals, reducing visits compared with monthly treatment.

Ordering through a Canadian pharmacy can offer 60–80 % savings versus typical US prices. Those paying without insurance often choose multi-month orders to lower per-month costs and reduce shipping frequency.

Beovu Pre-filled Syringe coupon details may appear on our promotions page from time to time.

Side Effects and Safety

• Common: eye pain or discomfort, conjunctival hemorrhage (small red patch on the white of the eye), foreign-body sensation, floaters, blurred vision, and transient increased eye pressure.
• Less common: corneal edema, photophobia, and mild intraocular inflammation.
• Post-injection events: temporary visual blur or irritation; driving should be avoided until vision clears.

Serious risks include endophthalmitis, intraocular inflammation, retinal vasculitis, and retinal arterial occlusion, which can threaten vision. Prompt assessment is required if vision decreases, floaters worsen, pain increases, or there is marked redness/sensitivity. Hypersensitivity reactions are possible. Beovu is contraindicated in active ocular or periocular infections and in active intraocular inflammation.

Onset Time

OCT-measured retinal fluid often improves within the first few weeks after the initial injection. Many patients notice visual stabilization or early gains during the loading phase. Maximal drying may follow the first 3 monthly doses, with maintenance dosing every 8 to 12 weeks. Vision outcomes vary based on baseline disease and treatment responsiveness.

Compare With Alternatives

Eylea® (aflibercept) is an anti-VEGF injection for wet AMD and DME. It is dosed monthly for several injections, then typically every 8 weeks, with some extended regimens. Efficacy is well established, and many clinics use aflibercept as a first-line option alongside brolucizumab.

Ranibizumab (Lucentis) is another anti-VEGF agent with monthly or treat-and-extend protocols. Some clinicians favor ranibizumab for long-term safety experience, while interval length can be similar to other options depending on response and protocol.

Faricimab (Vabysmo) targets both VEGF-A and Ang-2 and may allow longer intervals in selected patients. Regimen choice depends on diagnosis, prior response, and clinic protocols. For education on condition basics, review Age Related Macular Degeneration.

Combination Therapy

• Anti-VEGF monotherapy remains standard for wet AMD and DME in most cases.
• For DME, some patients also receive focal/grid laser during long-term management.
• Intravitreal steroids may be used in select DME cases; pressure monitoring is required.
• Avoid combining two anti-VEGF agents in the same eye; treatment plans are individualized.
• Systemic anticoagulants or antiplatelets are not routinely stopped solely for intravitreal injections; per clinician judgment.

Patient Suitability and Cost-Saving Tips

Beovu may be considered for adults with neovascular (wet) AMD or DME who need rapid fluid control and potential extension to 8–12 week intervals. It is not used when there is active ocular infection, intraocular inflammation, or known hypersensitivity to brolucizumab or excipients.

Precautions include pregnancy and breastfeeding, where risk–benefit discussions are needed due to limited human data. Transient vision changes can occur after injections, so arranging transportation on injection days is common practice. Patients with a history of intraocular inflammation or retinal vasculitis require careful evaluation.

To manage costs, consider multi-syringe orders when your prescriber has set ongoing therapy. Larger quantities can lower the per-month cost and reduce shipping fees. You can turn on reorder reminders in your account to avoid missed injections. This approach can help those purchasing without insurance or using a cash price.

Authoritative Sources

FDA Prescribing Information for Beovu (brolucizumab)

Health Canada Drug Product Database: Beovu

Novartis Beovu Product Page

Order Beovu® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This material is for educational purposes only and does not replace advice from your healthcare professional. Always follow your prescriber’s directions and clinic protocols.